Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA and Academician member of US national academy of sciences) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. He is also leading a group on nanopharmaceuticals at the CAS Center for Excellence in Nanoscience and Chief Lecture Professor of Nanobiology at University of Chinese Academy of Sciences.
Dr. Xing-Jie Liang is current editor-in-chief of Current Drug Delivery, deputy Editor-in-Chief of Biophysics Report and Associate Editor of Biomaterials, Advisory Board Member of ACS Nano. He is also current editorial board member of Bioconjugate Chemistry, Biomaterials Research, Theranostics and guest editor of Biotechnology Advances.
Dr. Liang was awarded with the Distinguished Young Scientists Grant by National Natural Science Foundation in 2012 and honored with the People's Republic of China State Council Special Allowance in 2010 as well as National Youth Science and technology innovation leader in 2017. Prof. Liang published over 280 peer-reviewed papers including articles in “Nature Nanotechnology